Alaunos Therapeutics reports Q1 net loss of $9.8M; first patient dosed in TCR-T Library trial

Alaunos Therapeutics, Inc.

2023-Q1 EPS reported -$0.05 vs consensus -$6.38 ▲ beat (+99.2%)

Net loss $9.8M ($0.05/sh) vs $21.6M ($0.10) in Q1 2021; cash $68.3M.
First patient dosed in TCR-T Library Phase 1/2 trial targeting KRAS, TP53, EGFR mutations across six solid tumors.
R&D expenses $5.6M (-58%), G&A $3.5M (-57%), operating cash burn $7.8M (-49%).
Preclinical data on mbIL-15 presented at ASGCT; IND expected H2 2023.
Initial clinical data expected H2 2022; cash runway into Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alaunos Therapeutics, Inc. reported three months ended March 31, 2022 results: net income Net loss was $9.8 million, or $(0.05) per share, EPS $(0.05) per share.

Period: three months ended March 31, 2022
Net income: Net loss was $9.8 million, or $(0.05) per share
EPS: $(0.05) per share
Result: reported results

Exact text from the filing

Alaunos Therapeutics, Inc. issued a press release announcing its financial condition and results of operations for the three months ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-150889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.